Vaccination data update, Jan. 3

Despite the holidays, several more states began reporting vaccination data in the past week. The Centers for Disease Control and Prevention (CDC) also made a huge update: this national dashboard is now posting vaccination counts at the state level.

Here are the notable updates:

  • I launched a vaccination data page on the CDD site which includes annotations on ten major national sources and every state’s vaccination reporting. I’ll be updating it weekly—the most recent update was yesterday.
  • Five states have started regularly reporting vaccination data since December 27: Alabama, Alaska, Indiana, Mississippi, and Wisconsin. 32 total states are now reporting these data; 15 states are reporting race and ethnicity of vaccinated residents. See more details on the resource page.
  • On December 30, the CDC started reporting state-level vaccination data on its national COVID-19 dashboard. For every state, the CDC is reporting total vaccine doses distributed and total people who have received their first dose. The dashboard also includes national counts—both for the U.S. as a whole and for long-term care facilities. Data are not yet available for download. According to the most recent update (yesterday, January 2), 4.2 million Americans have received their first dose.
  • Drew Armstrong, the Bloomberg reporter who runs the publication’s vaccination dashboard, posted a vaccine data user guide on Twitter. While the Tweet thread primarily describes the methodology and design choices behind Bloomberg’s dashboard, it also provides useful context for vaccination data overall. Two notable details: all vaccination data lag (the CDC’s data lag by about 50 hours, according to Armstrong), and Bloomberg is working on making the underlying data behind their dashboard public.
  • Benjy Renton halted updates for the “Doses Administered” tracker on his Vaccine Allocation Dashboard. As the CDC is now providing standardized state counts—and Renton is a one-person tracking operation—he’s switching to focus on analyzing vaccination trends and accessibility.  
  • Distribution delays: Operation Warp Speed promised that, if the Pfizer and Moderna vaccines received Emergency Use Authorization from the FDA, 20 million Americans would get vaccine doses by the end of 2020. That clearly didn’t happen. What went wrong? To answer that question, I recommend two articles: this STAT News story and this CNN story. Both articles suggest that a lag in data reporting may be one reason why the current vaccination counts look so low. Still, there’s a big difference between 4.2 million and 20 million.
  • Vaccination and the new COVID-19 strain: As the B.1.1.7 coronavirus variant, identified in the U.K., becomes an increasingly ominous threat to America’s COVID-19 containment, vaccination becomes increasingly urgent. Zeynep Tufekci’s latest piece in The Atlantic explains the issue. One piece that stuck out to me: the U.S. doesn’t have good genomic surveillance—or, a system to systematically sequence the virus genomes for people infected with SARS-CoV-2—which makes us less equipped to see where the new strain is actually spreading. As Tufekci puts it: “we are flying without a map.”
  • One dose or two? Scientists and public health leaders have been debating changing our vaccination protocol. Should the U.S. stick to the script, so to speak, and reserve enough vaccine doses that everyone who receives one dose can receive a second in the prescribed time window? Or should we give as many people first doses as we can, accepting that some may not get a second dose for months—or at all? (The U.K. opted for the latter earlier this week.) University of Washington professor Carl Bergstrom has compiled some Twitter threads that explain the debate. Dr. Fauci said on Friday that the U.S. will stick to the official two-dose regimen, but the scientific discourse will likely continue.

Related posts

  • there might be a link between the Oxford-AstraZeneca vaccine and those blood clots after all
    This week, authorities had enough data to posit a possible connection between blood clots known as cerebral venous sinus thrombosis (CVST) and the Oxford-AstraZeneca vaccine. The EMA has now advised, as of April 7, that “that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).” They are still recommending its use given the gravity of the COVID-19 pandemic, but it’s another blow to the vaccine that held much of the world’s hopes in inoculating the entire population. A mechanism by which the vaccine is causing these thromboses has not been discovered.
  • CDC says 80% of teachers and childcare workers are vaccinated, fails to provide more specifics
    This past Tuesday, April 6, the Centers for Disease Control and Prevention put out a press release that I found heartening, yet confusing. “Nearly 80 percent of teachers, school staff, and childcare workers receive at least one shot of COVID-19 vaccine,” the release proclaims. These vaccinations include “more than 2 million” people in these professions who received doses through the federal retail pharmacy program and “5-6 million” vaccinated through state programs, all of whom received shots before the end of March.
  • COVID source shout-out: New York expands eligibility
    This week, New York Governor Andrew Cuomo announced two major expansions for vaccine eligibility. State residents age 30 and older became eligible starting on March 30, and residents age 16 and older became eligible starting on April 6. This expansion allowed two of my favorite vaccine communicators to get their shots!
  • Pfizer for the whole pfamily
    Good news for people with kids: this week, Pfizer and BioNTech released results for their trial involving adolescents aged 12-15. In the trial, no participants who received the vaccine contracted symptomatic COVID-19 out of a total of 2,260 participants, marking an efficacy rate of 100%.

Leave a Reply